Capricor may qualify for a priority review voucher from the FDA if deramiocel receives marketing approval for the treatment of Duchenne muscular dystrophy.:
Source: Neurology Read More
Capricor Formally Submits BLA for Deramiocel in Duchenne Muscular Dystrophy Cardiomyopathy
Related Posts
<![CDATA[Beyond Neurodegeneration: GLP-1 Receptor
Agonists Find Their Footing in Stroke, Sleep, and Intracranial
Pressure Disorders]]>
<![CDATA[Beyond Neurodegeneration: GLP-1 Receptor Agonists Find Their Footing in Stroke, Sleep, and Intracranial Pressure Disorders]]>
